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BACKGROUND AND PURPOSE
Varenicline, a neuronal nicotinic acetylcholine receptor (nAChR) modulator, decreases ethanol consumption in rodents and
humans. The proposed mechanism of action for varenicline to reduce ethanol consumption has been through modulation of
dopamine (DA) release in the nucleus accumbens (NAc) via α4*-containing nAChRs in the ventral tegmental area (VTA).
However, presynaptic nAChRs on dopaminergic terminals in the NAc have been shown to directly modulate dopaminergic
signalling independently of neuronal activity from the VTA. In this study, we determined whether nAChRs in the NAc play a
role in varenicline’s effects on ethanol consumption.
EXPERIMENTAL APPROACH
Rats were trained to consume ethanol using the intermittent-access two-bottle choice protocol for 10 weeks. Ethanol intake
was measured after varenicline or vehicle was microinfused into the NAc (core, shell or core-shell border) or the VTA (anterior
or posterior). The effect of varenicline treatment on DA release in the NAc was measured using both in vivo microdialysis and
in vitro fast-scan cyclic voltammetry (FSCV).
KEY RESULTS
Microinfusion of varenicline into the NAc core and core-shell border, but not into the NAc shell or VTA, reduced ethanol
intake following long-term ethanol consumption. During microdialysis, a significant enhancement in accumbal DA release
occurred following systemic administration of varenicline and FSCV showed that varenicline also altered the evoked release of
DA in the NAc.
CONCLUSION AND IMPLICATIONS
Following long-term ethanol consumption, varenicline in the NAc reduces ethanol intake, suggesting that presynaptic nAChRs
in the NAc are important for mediating varenicline’s effects on ethanol consumption.
Abbreviations
α-CTXMII, α-conotoxin MII; DHβE, dihydro-β-erythroidine; NAc, nucleus accumbens; nAChR, nicotinic acetylcholine
receptor; VTA, ventral tegmental area.
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Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs; receptor
nomenclature see Alexander et al., 2013) are implicated as the
common molecular target for nicotine and ethanol and, in
recent years, have become a promising target for the devel-
opment of novel medications for alcohol dependence
(Chatterjee and Bartlett, 2010). These widely expressed recep-
tors are pentameric ligand-gated ion channels, consisting of
various heteromeric or homomeric combinations of α2–α10
and β2–β4 subunits (Zoli et al., 1998; Gotti et al., 2006).
Binding of acetylcholine (ACh, endogenous ligand) or nico-
tine (exogenous ligand) induces a conformational change in
the channel, allowing for an influx of cations; in contrast,
ethanol is not a direct agonist at nAChRs but can potentiate
the response of these receptors to ACh (Cardoso et al., 1999;
Zuo et al., 2002).
Through either direct or indirect modulation of nAChRs
located in the ventral tegmental area (VTA) and the nucleus
accumbens (NAc), ethanol and nicotine mediate neuronal
excitability and dopamine (DA) neurotransmission in the
mesolimbic pathway (Zhou et al., 2001; Ericson et al., 2003),
and thereby these receptors contribute significantly to the
reinforcing effects of these drugs. In the NAc, a limited array
of nAChR subtypes [α4β2, α6β2(β3), α4α6β2(β3) and α4α5β2]
have been identified on presynaptic dopaminergic terminals
that are important mediators of neurotransmitter release in
this region (Grady et al., 2002; Champtiaux et al., 2003). In
contrast, the VTA expresses a more diverse set of nAChR
subtypes that are localized extrasynaptically on somatoden-
dritic sites of dopaminergic neurons and modulate neuronal
excitation via membrane depolarization. Nicotinic receptors
in this region also significantly contribute to the regulation of
excitatory and inhibitory inputs to VTA dopaminergic cells
by their presynaptic location on GABAergic and glutamater-
gic terminal fields (Klink et al., 2001).
Varenicline, a partial agonist at α4β2*, α6β2* and α3β2*-
nAChRs (*denotes other possible subunits) and a full
agonist at α7 and α3β4* subtypes (Mihalak et al., 2006;
Grady et al., 2010), is a useful therapeutic agent for reducing
nicotine cravings and withdrawal symptoms (Garrison and
Dugan, 2009). The efficacy of varenicline for smoking ces-
sation is attributed to a dual action of (1) moderately
enhancing DA release in the NAc and (2) the attenuation
of nicotine-induced DA release by competitively blocking
the nAChR binding site (Rollema et al., 2007; 2010). In
addition, varenicline selectively decreases operant self-
administration and voluntary ethanol consumption in
rodents (Steensland et al., 2007; Hendrickson et al., 2010)
and attenuates alcohol drinking in humans (McKee et al.,
2009; Mitchell et al., 2012; Litten et al., 2013). The molecu-
lar mechanisms by which varenicline attenuates ethanol
consumption have not been completely elucidated. In mice,
intra-VTA infusion of varenicline decreases ethanol intake
after a short ethanol exposure by actions on the α4 subunit
of the nicotinic receptor (Hendrickson et al., 2010). The role
of nAChRs localized on presynaptic dopaminergic terminals
in the NAc has yet to be investigated for varenicline-
induced reductions in ethanol consumption. Given the
prominent role of the local cholinergic system in mediating
DA release in this region, varenicline may modulate
dopaminergic activity and subsequent drinking behaviours
through nAChRs in the NAc.
In the experiments presented here, we investigated the
role of the NAc in the effects of varenicline on ethanol intake
and probed for a mechanism of action using in vivo microdi-
alysis and in vitro fast-scan cyclic voltammetry (FSCV). The
present findings indicate that nAChRs in the NAc core and
core-shell border regions are important in mediating vareni-
cline’s effects on dopaminergic transmission and provide
further evidence that varenicline may be a useful treatment
for alcohol use disorders.
Methods
Drugs and chemicals
Ethanol (95% v v−1; Gold Shield Chemical Co., Hayward,
CA, USA) was diluted with dH2O to 20% solutions. Vareni-
cline (6,7,8,9-tetrahydro-6,10-methanol-6H pyrazino[2,3-
h][3]benzazepine tartrate) was generously provided by Pfizer
Global Research and Development (Groton, CT, USA). For
systemic injections, varenicline (1.0 mg kg−1, s.c.) dissolved in
saline (0.9%) or vehicle (saline, s.c.) was administered in a
volume of 1 mL kg−1, and ethanol (20%, 2.5 g kg−1, i.p.) or
vehicle (dH2O, i.p.) was administered during in vivo microdi-
alysis. For microinfusion experiments, varenicline (0.5, 1 and
2 µg) was dissolved in 10% potassium phosphate buffer/90%
isotonic saline solution, and thereafter, the pH was adjusted
to 7.4 with NaOH (1 N). Vehicle infusions consisted of 10%
potassium phosphate buffer/90% isotonic saline. The broad-
spectrum β2* nAChR-antagonist dihydro-β-erythroidine
(DHβE, 100 nM) and the α6* nAChR-selective antagonist
α-conotoxin MII [α-CTXMII at 30 nM concentrations has no
effect at non-α6/α3 nAChRs (Cartier et al., 1996)] were pur-
chased from Tocris Bioscience (Bristol, UK) and dissolved in
saline. Drug and molecular target nomenclature accords with
the British Journal of Pharmacology’s Concise Guide to Phar-
macology (Alexander et al., 2013).
Animals and housing
Male Wistar rats (weighing 150–175 g upon arrival; Harlan,
Indianapolis, IN, USA) were individually housed in ventilated
Plexiglas cages with ad libitum access to food and water. In
climate-controlled rooms (22 ± 2°C), rats were housed in a
reverse 12 h light/dark cycle room (lights off at 10:00 h). All
procedures were approved by the Ernest Gallo Clinic and
Research Center Animal Care and Use Committee and in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals, and the Animal
Research: Reporting In Vivo Experiments (ARRIVE) guidelines
(Kilkenny et al., 2010; McGrath et al., 2010).
Ethanol drinking paradigms
The intermittent-access two-bottle choice procedures com-
menced after acclimatization and 1 week of handling as
described by Wise (1973) and Simms et al. (2008). On
Mondays, Wednesdays and Fridays, rats were given access to
one bottle of ethanol (20% v v−1) and one bottle of water for
24 h; on all other days, two bottles of water were available for
24 h. Control rats had access to two water bottles at all times.
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The microinfusion, microdialysis and FSCV test sessions were
run on Wednesday or Friday; therefore, rats were 1 day
without ethanol. This protocol was used to establish long-
term ethanol consumption before rats were randomly
assigned to microinfusion (n = 51), microdialysis (n = 29) or
FSCV (n = 29) experiments.
Surgical procedures
After 8–10 weeks of ethanol exposure in the two-bottle choice
paradigm, rats underwent a surgical procedure to place guide
cannulae (Plastic One, Roanoke, VA, USA) above the brain
region of interest to allow for microinjections or in vivo
microdialysis. Animals were deeply anaesthetized, unrespon-
sive to toe pinch, with 2.5% isoflurane (VetEquip, Pleasanton,
CA, USA) vaporized in oxygen at a flow rate of 0.6–
0.8 L min−1. For the microinfusion studies, a 26 guage bilat-
eral guide cannula assembly (Plastics One, Inc.) was
stereotaxically implanted using the following coordinates
from bregma with a flat skull: anterior VTA (AP: −5.0, ML:
±1.6, DV: −8.8, 6° angle); posterior VTA (AP: −5.8, ML: ±2.1,
DV: −8.8, 10° angle); NAc shell (AP: +2.2, ML: ±0.75, DV:
−7.8); NAc core (AP: +1.6, ML: ±1.5, DV: −7.2); NAc core-shell
border (AP: +1.6, ML: ±1.0, DV: −7.4). The DV coordinates
represent the location of the microinjector tips. For the
microdialysis experiment, a unilateral guide cannula (21
guage; Plastics One, Inc.) was implanted with the following
coordinates aimed above the NAc core-shell border (AP: +1.6,
ML: + or −1.0, DV: −4.0). The core-shell border region, defined
by our group, refers to the area where the NAc core and shell
borders meet; therefore, this region may include portions of
both the medial core and dorsal shell especially when drug
diffusion is accounted for. Microinjection tips within the NAc
shell region were confined to the medial/ventral shell, but
through tissue diffusion, the drug could possibly have
reached surrounding areas, for example, olfactory tubercle or
islands of callejo. Cannulae were fixed to the head with four
stainless steel screws (Plastics One, Inc.) and dental cement
(Lang Dental Inc., Wheeling, IL, USA). Rats were allowed to
recover for approximately 5–7 days after surgery before
returning to the drinking paradigm.
Microinjection procedures
After long-term ethanol exposure (8–10 weeks), rats under-
went surgery and were returned to the two-bottle choice
paradigm for at least 2 weeks. Before microinfusions com-
menced (average daily ethanol consumed 6.04 ± 0.27 g kg−1
per 24 h), rats were handled (5 min) on several occasions for
habituation to procedures. On test days, 1 µL syringes (Ham-
ilton Company, Reno, NV, USA) mounted on a microdrive
pump (Harvard Apparatus, Holliston, MA, USA) infused
0.5 µL of varenicline (0.5, 1 or 2 µg) or vehicle through poly-
ethylene tubing (PE-50, Clay Adams brand; Becton Dickin-
son, Franklin Lakes, NJ, USA) into bilateral injectors (33
guage; Plastics One, Inc.) at a rate of 0.125 µL min−1 for 4 min.
Injectors remained in place for an additional 2 min to allow
for diffusion. Rats were placed back in home cages and drink-
ing sessions commenced 10 min after infusions. By Latin
square design, subjects received every dose (balanced order)
with 1 week between treatments. The ethanol consumption
data were analysed using one-way repeated measures ANOVA,
followed by Newman–Keuls post hoc tests.
Fast-scan cyclic voltammetry
FSCV was performed using carbon-fibre microelectrodes (tip
length 50 −100 µm) constructed in house with 7 µm carbon
fibre and glass electrodes (Warner Instruments, Hamden, CT,
USA). The electrode potential was scanned with a triangular
waveform (from −0.4 to 1.3 V range vs. Ag/AgCl reference
electrode) at a scan rate of 400 V·s−1 and a sampling frequency
of 10 Hz (Figure 1B). Data acquisition and triangle waveform
generation were controlled by TarHeel CV hardware and soft-
ware (University of North Carolina, Chapel Hill, NC, USA).
Long-term ethanol-consuming rats (>10 weeks; average
daily ethanol consumed 5.45 ± 0.26 g kg−1) and age-matched
water controls without any previous varenicline treatments
were deeply anaesthetized with sodium pentobarbital
(10 mg kg−1, i.p.) and then perfused with an ice-cold sucrose
solution consisting of NaCl (125 mM), KCl (1.6 mM),
NaH2PO4 (1.1 mM), NaHCO3 (25 mM), CaCl2 (0.1 mM),
MgCl2 (1.4 mM), sucrose (50 mM) and glucose (1.2 mM). The
brains were sliced with a Leica Microsystems VT1200S
Vibratome (300 µm coronal slices; Leica, Wetzlar, Germany)
and slices were kept in a 32°C bicarbonate-buffered ACSF
containing CaCl2 (2.4 mM) and glucose (11 mM). After at
least 1 h of incubation, brain slices were transferred to a
submersion recording chamber and perfused with 30°C oxy-
genated ACSF.
Recording sites were made in the NAc core-shell border,
medial to the anterior commissure that encompass sites
within both the NAc core and the shell (approximately
within the areas denoted in Figure 2C), with the tungsten
matrix electrodes placed (∼100–200 µm) away from the
recording electrode (115 µM spacing, FHC). DA release was
evoked at 3 min intervals by alternating a single electrical
(250 µs duration, 0.6 mA) pulse (1p), which simulated ‘tonic’
dopaminergic activity, with a burst of four pulses (4p,
100 Hz), which simulated dopaminergic neuron firing rates
that occur after presentation of a reward or a conditioned
reward-related cue. After recordings were made in physiologi-
cal buffer (ACSF), the non-selective nAChR agonist/partial
agonist varenicline (0.1 or 10 µM), the β2* nAChR antagonist
DHβE (100 nM) or the α6* nAChR antagonist α-CTXMII
(30 nM) were bath-applied for 10 min before data were col-
lected. After background currents were digitally subtracted,
peak oxidation (0.6 mV) and reduction (−0.2 mV) currents
were converted into [DA]o after post-experimental calibration
of the carbon fibre electrode, made by scanning fresh DA
standards (1–2 µM) in ACSF. Data are presented as mean peak
[DA]o levels (normalized to ACSF control 1p) after single (1p)
and multiple (4p) stimulation pulses and as the average ratio
of [DA]o released by 1p and 4p to depict the relative simulated
phasic-to-tonic response. A two-way repeated measures ANOVA
followed by Bonferroni’s post hoc tests was used to analyse the
average ratio [DA]4p/[DA]1p of the DA signal evoked by 1p and
4p (normalized to control ACSF 1p) during control condi-
tions and after drug application.
In vivo microdialysis procedures
Microdialysis probes were constructed according to proce-
dures previously described (Duvauchelle et al., 2000), with a
2.5 mm active membrane extending 4.5 mm beyond the end
of the cannula. Before probe implantation, recovery values
BJP A A Feduccia et al.
3422 British Journal of Pharmacology (2014) 171 3420–3431
for each probe were calculated by measuring in vitro samples
(peak heights) and comparing them to known DA standards.
The mean (±SEM) DA recovery of probes used in these experi-
ments was 15.08 ± 0.49%. Rats were briefly anaesthetized
with isoflurane to implant probes at least 12 h prior to the
microdialysis test session. Animals remained in a test
chamber overnight while artificial cerebral spinal fluid
(ACSF: 145 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 1.2 mM
CaCl2, pH 7.4 adjusted with NaOH) was pumped (Harvard
Apparatus) through the probe at a rate of 0.2 µL min−1 with
a 1.0 mL glass syringe (Hamilton Company). The pump
speed was increased to 1.0 µL min−1 1 h before the test session
commenced.
After long-term ethanol exposure (>10 weeks; average
daily ethanol consumed 5.14 g kg−1 per 24 h) in the two-
bottle choice procedure, microdialysis was performed to
measure DA release in the NAc core-shell border. Dialysate
samples were collected at 20 min intervals through previ-
ously implanted probes; baseline samples were collected
for 40 min and then rats were administered varenicline
(1.0 mg kg−1, s.c.) or vehicle (saline, s.c.) and immediately
placed back into the chambers. After 40 min, rats were given
a second injection of ethanol (2.5 g kg−1, i.p.) or vehicle
(dH2O, i.p.), and samples were collected for an additional
100 min.
To determine in vivo extracellular concentrations of DA,
dialysate samples were analysed by HPLC with electrochemi-
cal detection [HPLC-EC; microtitre model 540, Capcell C-18
narrow bore column (1.5 mm I.D. × 50 mm × 3 µm; Shiseido,
Tokyo, Japan), model 5200A Coulochem III Detector, model
5041 cell (oxidizing potential: +220 mV) and model 5020
guard cell (potential: +275 mV); ESA, Inc., Chelmsford, MA,
USA]. A dual-piston HPLC pump (model 584; ESA, Inc.) cir-
culated mobile phase [sodium dihydrogen phosphate
(75 mM), citric acid (4.76 mM), SDS (3 mM), EDTA (0.5 mM),
methanol 8% and acetonitrile 11% (v v−1), pH adjusted to 5.6
with NaOH] through the system at a flow rate of
0.2 mL min−1. DA concentrations from samples were quanti-
fied by comparing peak heights to external standards. Statis-
tical analysis of dialysate extracellular DA levels (% of basal)
during baseline, 40 min after the first injection (1.0 mg kg−1
varenicline or vehicle) and 100 min after the second injection
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Figure 1
Local varenicline infusion into the NAc (core and core-shell border) reduces voluntary ethanol (20%) consumption in the intermittent-access
two-bottle choice paradigm. Values are expressed as mean ethanol intake (g kg−1) ± SEM 30 min after the start of the drinking sessions (n = 8–12
per brain region, one-way repeated measures ANOVA followed by Newman–Keuls post hoc tests. *P < 0.05, **P < 0.01 compared with vehicle).
Varenicline microinfusion significantly reduced ethanol intake (g kg−1) in the (A) NAc core and (B) NAc core-shell border, but had no effect on
ethanol consumption when infused into the (C) NAc shell, (D) posterior VTA or (E) anterior VTA.
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(2.5 g kg−1 ethanol or vehicle) were analysed using two-way
(time × treatment) repeated measures ANOVA with Bonferroni’s
post hoc tests.
Histology
At the end of the experiments, rats were anaesthetized with
isoflurane (VetEquip), and brains were removed, stored in
10% formalin for 1 week and 20% sucrose for at least 3 days
before being sectioned (30 µm) and stained with cresyl violet.
Histological analysis verified cannula placements to be in the
correct position within a given brain region.
Results
Microinfusion of varenicline
To examine the effect of varenicline on ethanol intake,
varenicline (0.5, 1 or 2 µg) or vehicle was directly infused into
the NAc (core, core-shell border or shell) or varenicline (1 or
2 µg) or vehicle into the VTA (anterior and posterior) of rats
chronically drinking ethanol in the two-bottle choice model
(n = 8–12 animals per brain region). Microinfusion of vareni-
cline (0.5, 1 or 2 µg) into the NAc core-shell border [F(3, 43)
= 6.16, P < 0.01] and varenicline (2 µg) into the NAc core [F(3,
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Figure 2
Histological analysis verified cannula placements to be in the correct position. Representative coronal brain sections (Paxinos and Watson, 1997)
with respect to bregma showing the accepted placements of (A) active membrane regions of microdialysis probes in the Nac, (B) bilateral infusion
cannula tips in the anterior and posterior VTA and (C) bilateral infusion cannula tips in the NAc shell, core and core-shell border.
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47) = 3.74, P < 0.05] significantly attenuated ethanol con-
sumption (g kg−1 per 30 min), whereas infusion into the NAc
shell or VTA (anterior and posterior) did not (Figure 1).
Varenicline or vehicle infusions did not affect water intake
(30 min, 4 and 24 h) or ethanol intake (4 and 24 h) (Table 1).
Fast-scan cyclic voltammetry
To determine whether varenicline has a direct effect on DA
release in the NAc that is distinct from VTA modulation of DA
transmission in the NAc, we used FSCV with slices prepared
from animals consuming ethanol to measure DA levels
evoked by stimuli of 1 pulse (1p) and 4 pulses (4p) to simulate
tonic and phasic firing, respectively, as described by Hyland
et al. (2002) and Rice and Cragg (2004). We selected the NAc
core-shell border NAc as the results from the microinfusion
studies showed this region to mediate the effect of varenicline
on ethanol consumption. We identified two distinct popula-
tions of neurons within NAc core-shell border (k-means
cluster analysis, F ratio = 231.9, P < 0.0001), one under
control of nAChRs and the other not. This was determined by
measuring DA concentrations (µM) evoked by stimuli of 1p or
4p during control conditions (ACSF). If a large ratio [DA]4p/
[DA]1p was initially detected, then subsequent treatment
with the nicotinic receptor drugs (varenicline, DHβE and
α-CTXMII) did not change the magnitude of evoked DA
compared with ACSF control conditions (data not shown),
indicating minimal control of DA release probability by
nAChRs in this subset of neurons, as described by Exley et al.
(2008). On the contrary, a small ratio during control condi-
tions has been associated with ACh acting on β2*-nAChRs to
promote DA release during a single action potential but lim-
iting release during successive pulses by short-term depres-
sion of DA synapses (Landgren et al., 2012). A similar finding
has been reported for the NAc core (ventral to the anterior
commissure) where a small portion of recording sites (∼20%)
lacked strong control by nAChRs (Exley et al., 2008). To
understand the role of nAChRs, only sites with a similar ratio
[DA]4p/[DA]1p during ACSF control tests were included in the
following analyses.
We measured peak DA (µM) levels in the NAc of slices
from long-term drinking rats (0.1 and 10 µM), α-CTXMII
(30 nM) and DHβE (100 nM). All treatments (n = 6–8 per
treatment) significantly [F(3, 51) = 5.29, P < 0.01] enhanced
the ratio [DA]4p/[DA]1p compared with ACSF control, and
there was no difference in the magnitude of response
between treatments or rat groups (Figure 3C). To quantify the
direction and magnitude of change, a two-way repeated
measures ANOVA of [DA]o (normalized to ACSF control 1p)
release revealed that average evoked [DA]o levels after appli-
cation of drug treatments was significantly [F(9, 153) = 2.12,
P < 0.05] different than control conditions and depending
upon the treatment either decreased DA release after 1p,
increased DA release after 4p or was bidirectional (Figure 3A
and D). For ethanol-experienced rats, varenicline (0.1 µM)
and DHβE (100 nM) altered DA release probability, reducing
evoked [DA]o after 1p and an increasing evoked [DA]o after 4p.
Table 1
Varenicline or vehicle infusions do not affect water intake (30 min, 4 and 24 h) or ethanol intake (4 and 24 h)
Brain region Treatment
Water intake (mL) Ethanol intake (mL)
30 min 4 h 24 h 4 h 24 h
NAc core Vehicle 1.8 ± 0.3 7.9 ± 0.7 22.5 ± 2.8 2.1 ± 0.2 4.8 ± 0.5
Varenicline (0.5 µg) 1.5 ± 0.2 8.2 ± 0.8 24.3 ± 2.4 2.0 ± 0.2 4.5 ± 0.5
Varenicline (1 µg) 1.8 ± 0.5 6.1 ± 1.0 23.4 ± 2.7 2.0 ± 0.2 4.5 ± 0.6
Varenicline (2 µg) 1.2 ± 0.3 8.0 ± 1.0 24.4 ± 2.4 1.8 ± 0.2 4.1 ± 0.5
NAc core-shell border Vehicle 1.5 ± 0.4 5.5 ± 0.7 15.0 ± 1.7 2.1 ± 0.1 4.9 ± 0.5
Varenicline (0.5 µg) 1.6 ± 0.3 5.4 ± 0.7 15.1 ± 1.5 1.8 ± 0.1 4.8 ± 0.4
Varenicline (1 µg) 1.3 ± 0.4 5.8 ± 0.8 18.1 ± 1.9 1.8 ± 0.2 4.4 ± 0.5
Varenicline (2 µg) 1.4 ± 0.3 5.5 ± 0.6 17.9 ± 2.2 1.9 ± 0.2 4.7 ± 0.5
NAc shell Vehicle 1.4 ± 0.3 10.8 ± 1.4 28.1 ± 3.3 2.0 ± 0.2 4.6 ± 0.5
Varenicline (0.5 µg) 1.4 ± 0.4 8.6 ± 0.8 26.3 ± 2.7 2.2 ± 0.3 5.4 ± 0.5
Varenicline (1 µg) 1.3 ± 0.3 10.5 ± 3.7 24.2 ± 2.5 2.2 ± 0.2 5.4 ± 0.6
Varenicline (2 µg) 1.7 ± 0.5 9.3 ± 1.0 26.4 ± 1.9 2.2 ± 0.2 5.5 ± 0.5
Posterior VTA Vehicle 0.6 ± 0.2 6.4 ± 1.1 14.5 ± 1.4 2.3 ± 0.1 5.4 ± 0.4
Varenicline (1 µg) 0.8 ± 0.2 5.4 ± 0.7 14.4 ± 2.9 2.4 ± 0.2 5.9 ± 0.4
Varenicline (2 µg) 1.1 ± 0.3 4.9 ± 0.7 13.2 ± 2.5 2.6 ± 0.3 6.2 ± 0.5
Anterior VTA Vehicle 0.7 ± 0.2 5.5 ± 0.7 16.3 ± 1.9 2.0 ± 0.2 4.6 ± 0.5
Varenicline (1 µg) 1.1 ± 0.4 7.2 ± 1.4 17.1 ± 2.4 2.2 ± 0.2 5.2 ± 0.7
Varenicline (2 µg) 0.6 ± 0.1 5.3 ± 0.8 17.7 ± 2.3 2.1 ± 0.3 5.0 ± 0.6
The values are expressed as mean water or ethanol intake ± SEM after microinfusion of varenicline or vehicle (one-way repeated measures
ANOVA; n.s.).
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Figure 3
Evoked DA release in slices from ethanol-drinking and water control rats measured by FSCV in the NAc core-shell border region. Varenicline
modulates DA release by desensitizing presynaptic nAChRs in the NAc core-shell border. (A) Representative DA traces evoked (100 Hz, 0.6 mA) by
stimuli of one pulse (1 pulse, solid lines) or four pulses (4 pulses, dashed lines) in control ACSF and after varenicline (0.1 and 10 µM), α-CTXMII
(30 nM) and DHβE (100 nM). (B) Typical DA voltammogram elicited by one 0.6 mA pulse of 250 µs duration. (C, D) Data represent DA signals in
the NAc of slices from ethanol-exposed and water control rats evoked by a single pulse (1p) or a train of 4 pulses (4p) at 100 Hz in the absence (ACSF)
or presence of varenicline (0.1 or 10 µM), α-CTXMII (30 nM) and DHβE (100 nM), n = 6–8 per treatment. (C) The average ratio [DA]4p/[DA]1p of the
DA signal evoked by 1p and 4p (normalized to control ACSF 1p) in ethanol-exposed rats or water control rats. All treatments significantly enhanced
the ratio [DA]4p/[DA]1p compared with ACSF control. There was no difference between ethanol and control animals (three-way repeated measures
ANOVA followed by Bonferroni’s post hoc tests, ***P < 0.001 compared with ACSF control). (D) Average peak [DA]o levels (normalized to ACSF control
1p) after stimulation pulses (1p and 4p) in the NAc of ethanol-exposed (top panel) or water control (bottom panel) rats (three-way repeated
measures ANOVA followed by Bonferonni’s post hoc tests, *P < 0.05, **P < 0.01, ***P < 0.001 compared with ACSF control).
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Conversely, varenicline (10 µM) reduced evoked [DA]o after
1p and did not alter release stimulated by 4p. In control rats,
varenicline (1 and 10 µM) reduced evoked [DA]o after 1p and
increased release stimulated by 4p, whereas DHβE (100 nM)
reduced [DA]o evoked by 1p but displayed no significant
change after 4p. For both ethanol and control rats, the α6β2*
nAChR antagonist α-CTXMII (30 nM) treatment evoked
[DA]o by 4p was greater compared with ACSF control condi-
tions but not significantly different after a single pulse.
In vivo microdialysis test session
Previously, it has been shown that systemic administration of
varenicline in naïve animals leads to an increase in DA release
(Ericson et al., 2009); however, the effect of systemic admin-
istration of varenicline and ethanol on DA release in the
NAc in rats with a history of ethanol consumption has never
been examined. During in vivo microdialysis, varenicline
(1.0 mg kg−1, s.c.) significantly enhanced extracellular DA
release (% of basal) in the NAc core-shell border compared
with vehicle during the 40 min period (Figure 4A) after the
injection [F(3, 54) = 6.35, P < 0.01, n = 8–12 per treatment].
After the second injection of ethanol (2.5 g kg−1, i.p.) or
vehicle [F(8, 60) = 5.36, P < 0.01], rats receiving varenicline +
ethanol (n = 6) had significantly greater DA levels compared
with groups that were treated with varenicline + vehicle
(Figure 4B; first time point, P < 0.05, n = 6) or vehicle +
ethanol (Figure 4A; second time point, P < 0.05, n = 6). Similar
results were obtained in the animals consuming water only
(Supporting Information Fig. S1). The DA concentrations
(uncorrected) in basal samples were 1.14 ± 0.19 nM.
Discussion
Our findings demonstrate for the first time that local infusion
of varenicline into the NAc core or core-shell border, but not
into the NAc shell or VTA, significantly attenuates ethanol
consumption in long-term ethanol-consuming animals.
Specifically, varenicline modulates DA release by acting on
pre-synaptic nAChRs on dopaminergic terminals in the NAc
through a similar mechanism described for nicotine and
nAChR antagonists (Zhou et al., 2001; Zhang and Sulzer,
2004).
Our results show that varenicline increases extracellular
DA concentrations in the NAc after long-term ethanol con-
sumption and confirms previous findings for naïve rats (Coe
et al., 2005; Rollema et al., 2007; Ericson et al., 2009), thus
indicating that chronic ethanol consumption does not alter
the ability of varenicline to increase DA release in the NA.
Figure 4
Varenicline enhances NAc DA levels but does not block ethanol-
stimulated DA release measured by in vivo microdialysis in rats with
a history of voluntary ethanol consumption. Data represent NAc
extracellular DA levels (% mean basal ± SEM) before (basal) and after
rats were pretreated with varenicline (1.0 mg kg−1, s.c.) or vehicle
followed by a second injection 40 min later of either ethanol
(2.5 g kg−1, i.p.) or vehicle. (A) Pretreatment with varenicline
(1.0 mg kg−1, s.c.) significantly enhanced extracellular DA release in
the core-shell border of the NAc compared with vehicle (grey panel,
*P < 0.05) during the 40 min period after the injection (two-way
repeated measures ANOVA followed by Bonferonni’s post hoc tests, n =
8–12 per treatment). After a second injection of ethanol (2.5 g kg−1,
i.p.) or vehicle, rats that received varenicline + ethanol had signifi-
cantly greater DA levels (*P < 0.05) compared with the groups that
were treated with vehicle + ethanol (two-way repeated measures
ANOVA followed by Bonferonni’s post hoc tests, n = 6 per treatment).
(B) After a second injection of ethanol (2.5 g kg−1, i.p.) or vehicle, rats
that received varenicline + ethanol had significantly greater DA levels
(*P < 0.05) compared with the groups that were treated with vareni-
cline + vehicle (two-way repeated measures ANOVA followed by Bon-
feronni’s post hoc tests, n = 6 per treatment).
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Varenicline does not block ethanol-stimulated DA release,
and ethanol treatment alone exerts a similar relative increase
in DA independent of the pretreatment condition (i.e. vehicle
or varenicline). This suggests that varenicline and ethanol
have independent mechanism of actions for enhancing DA
levels in the NAc. In contrast, varenicline competitively
blocks nicotine from the binding site and effectively reduces
nicotine-induced DA elevation in vivo by 40–55% (Rollema
et al., 2007). Our results are in agreement with the studies
showing that varenicline (1.5 mg kg−1, s.c.) pretreatment does
not reduce DA release following a single acute ethanol
(2.5 g kg−1, i.p) injection (Ericson et al., 2009). However, this
differs from the experiment showing that concomitant
administration of varenicline and ethanol blocked DA
enhancement in naïve rats (Ericson et al., 2009). This differ-
ence may be due to the fact that we administered varenicline
before ethanol rather than at the same time.
In the NAc, ACh is released by a small population of large,
aspiny cholinergic interneurons with extensive arborization
(Phelps et al., 1985) that subsequently modulates nAChRs
expressed on dopaminergic terminals (Zhou et al., 2002).
ACh acting on presynaptic β2*-nAChRs promotes DA release
during tonic activity but limits release probability during
high-frequency, phasic bursts by contributing to short-term
depression of DA synapses. In studies utilizing FSCV, blocking
these receptors with nAChR antagonists or via agonist-
induced desensitization will facilitate DA release during burst
firing but will inhibit release during tonic activity (Zhou et al.,
2001). This model proposes that a reduction in nAChR func-
tion will increase the ratio between tonic and phasic firing
patterns, thereby amplifying the signal elicited by reward-
associated cues or reinforcers and reducing the effect of tonic
dopaminergic activity (Landgren et al., 2012).
As an infusion of varenicline into the NAc core or core-
shell border regions reduced voluntary ethanol intake follow-
ing long-term ethanol consumption in rats, we used FSCV to
explore the hypothesis that varenicline locally modulates DA
outflow in this region. Varenicline, DHβE and α-CTXMII all
significantly increased the contrast between high-and-low
frequency evoked DA signals. The α4* and α6* nAChR
antagonist DHβE increased DA release after 4p and inhibited
release after a 1p in ethanol-consuming rats. In contrast, the
effects of the α6* nAChR antagonist α-CTXMII on DA release
probability occurred only after 4p. This suggests that the α4*
nAChRs mediate the reduction in DA release after 1p and the
α6* nAChRs mediate the effects that increase DA release after
4p in long-term ethanol-consuming rats. This supports the
findings of other investigators that have shown that there are
clear regional differences in the control of dopaminergic
transmission between the NAc core and the dorsal striatum
(Exley et al., 2008; 2012), and findings from our experiments
point to a unique, subunit-specific control of DA release by
nAChRs in the NAc core-shell border region. The lowest con-
centration of varenicline (0.1 µM) increased DA release after
4p and decreased DA release after 1p, suggesting that both
α4* and α6* nAChR subunits mediate this effect. In contrast,
higher doses of varenicline (10 µM) lead to a decrease in DA
release after 1p and did not change DA release after 4p,
suggesting that the α4* nAChR subunit plays a major role in
this effect after long-term consumption of ethanol. During
intermittent access to ethanol, there are days when the
animals do not have access to ethanol and this may have
significant implications for the neurochemical response to
varenicline and may explain why there are differences
between drug treatment responses in the ethanol-consuming
and control animals. Despite the characteristic directional
changes, all treatments resulted in a similar [DA]4p/[DA]1p
ratio, which may relay similar information regarding the
frequency of firing rates of dopaminergic neurons; however,
these directional variations may also be interpreted differen-
tially post-synaptically.
The infusion of varenicline into the NAc core or core-shell
border region reduced ethanol consumption, whereas infu-
sions into the medial NAc shell had no effect. Although
numerous anatomical and functional differences exist
between the NAc subregions (Bassareo and Di Chiara, 1999),
the heterogeneous nAChR distribution and cholinergic inner-
vation offer a probable explanation for the inconsistencies in
the results between regional injection sites in our experiment.
Most notably, immunohistochemical evidence shows a
prominent band of cholinergic fibres along the border
between the NAc core and shell (Zaborszky et al., 1985;
Meredith et al., 1989). The core-shell border may be a distinct
site for the dopaminergic response to ethanol, indicated by a
report showing only this area (not the NAc core or shell) had
a significant increase in DA outflow during operant ethanol
self-administration (Howard et al., 2009). A study utiliz-
ing FSCV (Zhang et al., 2009) demonstrated substantial
frequency-dependent differences during control conditions
between subregions, with the NAc shell exhibiting a much
larger evoked tonic-to-phasic ratio compared with the NAc
core. Additionally, DHβE inhibition of nAChRs was less effec-
tive in the NAc shell compared with the dorsolateral striatum
and, in fact, the ratio ([DA]5p/[DA]1p at 20 Hz) and frequency-
dependent facilitation of DA release in the NAc shell was
similar to mutant mice lacking the nAChR β2 subunit. Taken
together, these findings suggest only a modest role of nAChRs
in the NAc shell on DA release probability and offer a plau-
sible explanation for the lack of response to microinfusion of
varenicline into the NAc shell.
Treatment with nAChR antagonists, such as mecamyla-
mine (non-selective nAChR antagonist), also decrease
ethanol consumption in rats when administered systemically
(Blomqvist et al., 1996; Le et al., 2000) or directly into the
anterior VTA by blocking ethanol-induced DA release in the
NAc (Blomqvist et al., 1997; Ericson et al., 1998). Further-
more, mecamylamine infused into the NAc does not
block ethanol-induced DA release (Blomqvist et al., 1997;
Söderpalm et al., 2000) but does reduce ethanol self-
administration (Nadal et al., 1998), presumably through
desensitization of pre-synaptic nAChRs in the NAc. This
shows that it is possible to reduce ethanol self-administration
in rats by blocking ethanol-induced DA release via nAChRs in
the VTA and by increasing accumbal DA release. It has been
shown that intra-VTA varenicline infusions reduce ethanol
consumption in mice after short-term ethanol exposure
(Hendrickson et al., 2010), an unexpected finding from our
study was that varenicline administered directly into the
anterior or posterior VTA had no effect on ethanol consump-
tion in long-term ethanol-consuming rats. The most likely
explanation is the significant methodological differences
between the studies such as the species, varenicline doses and
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the duration of ethanol exposure prior to varenicline testing
(days vs. months). Recent studies utilizing optogenetic and
electrophysiological techniques have demonstrated that acti-
vation of cholinergic interneurons in the NAc is sufficient to
evoke DA release by actions on pre-synaptic nAChRs and does
not require action potentials generated by DA soma in the
VTA. Thus, activity of cholinergic interneurons and nAChRs
in the NAc may also be important for conveying DA signals
than previously thought and may profoundly affect the
outcome of ascending DA neuron firing activity (Cachope
et al., 2012; Threlfell et al., 2012).
Intra-NAc varenicline infusions significantly attenuated
ethanol consumption but not to the full extent of systemic
administration, indicating that, in addition to the NAc, there
are likely other brain regions and/or nAChR subtypes respon-
sible for varenicline’s effects. For example, varenicline is a full
agonist at α3β4 nAChRs (Mihalak et al., 2006; Grady et al.,
2010), which are densely concentrated in regions that play a
significant role in reward processing such as the medial
habenula and interpeduncular nucleus (Nishikawa et al.,
1986; Grady et al., 2009). The high-affinity α3β4 nAChRs
partial agonists, CP-601932 and PF-4575180, reduce ethanol
consumption in rodents (Chatterjee et al., 2011), indicating
that varenicline’s mechanism of action may also be attributed
to this receptor subtype. Also, varenicline reduced ethanol
consumption in mice lacking the β subunits (Kamens et al.,
2010). Based upon these studies, we hypothesize that the
effects of varenicline on ethanol consumption result from
activation and desensitization of nAChRs in multiple brain
circuits.
Taken together, our findings show that varenicline
enhances DA release in the NAc following long-term ethanol
consumption and nAChRs localized on presynaptic dopa-
minergic terminals in the NAc core and core-shell border play
a prominent role in the effects of varenicline on ethanol
consumption, suggesting that nAChRs are an important
therapeutic target for alcohol use disorders.
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Figure S1 Varenicline enhances NAc DA levels but does not
block ethanol-stimulated DA release measured by in vivo
microdialysis in both ethanol-exposed and water control rats.
Data represent NAc extracellular DA levels (% mean basal ±
SEM) before (basal) and after rats were pretreated with vareni-
cline (1.0 mg kg−1, s.c.) or vehicle followed by a second injec-
tion 40 min later of either ethanol (2.5 g kg−1, i.p.) or vehicle
(two-way repeated measures ANOVA; n.s.). The magnitudes of
the responses to varenicline and ethanol treatments were
similar between ethanol-exposed (n = 6–12 per treatment)
and water control rats (n = 3–6 per treatment).
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